New research further supports Proteocyte Diagnostic’s Straticyte™ as a more accurate and objective early cancer and precancer assessment tool

Toronto, ON; May 8, 2014 – The scientific foundation of Proteocyte Diagnostic’s Straticyte™ technology was presented at the 2014 Annual Conference of the Academy of Oral and Maxillofacial Pathology (AAOMP), at St. Augustine, Florida. The poster, ‘Molecular signature for predicting risk of cancer development in oral lesions with dysplasia’, presents the clinical significance of biomarker S100A7 in stratifying the risk of malignancy of oral dysplastic lesions.

Identification of oral lesions with dysplasia at high risk of becoming cancerous remains a major clinical challenge. Currently, there are no biomarkers that can be used in clinics to predict these high risk lesions. Proteocyte Diagnostics’ Straticyte technology, based on assessment of cancer biomarkers including S100A7, offers objective and accurate early diagnosis of precancers and cancers.

Members of the research team include Dr. Ranju Ralhan, Co-Director of the Shnaider Laboratory and a Canadian Institutes of Health Research Chair in Advanced Cancer Diagnostics and Dr. David Mock, Department of Oral Pathology and Oral Medicine, Faculty of Dentistry, University of Toronto.

“These findings and their application in the clinical setting are of immense importance for identifying patients in whom early intervention prior to cancer development will lead to more effective disease management,” said Dr. David Mock, who presented the poster on behalf of the research team. “Straticyte will permit earlier, less traumatizing personalized treatment for patients.”

The Academy of Oral and Maxillofacial Pathology (AAOMP) represents the dental specialty that identifies and manages diseases affecting the oral and maxillofacial regions and investigates the causes, processes and effects of these diseases.

About Proteocyte
Proteocyte Diagnostics Inc. is a Canadian molecular diagnostics company that develops and commercializes a novel diagnostics technology, Straticyte™ that offers objective and accurate early diagnosis of precancers and cancers. The company’s first product objectively and accurately distinguishes between those precancerous oral lesions at high risk of becoming cancerous and those that pose low risk. Early diagnosis of high risk lesions permits more effective and less traumatizing treatments. By identifying and treating oral cancer before it happens, clinicians can save lives, healthcare costs are reduced and quality of life of patients is improved. Identifying more accurately low risk pre-cancerous lesions avoids unnecessary surgeries and allows clinicians to monitor patients regularly for peace of mind.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.